Asvin K. Lakkaraju

Zurich, ZH 8091, Switzerland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Channel Activities of the Full-Length Prion and Truncated Proteins.

Channel Activities of the Full-Length Prion and Truncated Proteins.

Journal: ACS chemical neuroscience

Published: December 14, 2023

An arrayed genome-wide perturbation screen identifies the ribonucleoprotein Hnrnpk as rate-limiting for prion propagation.

An arrayed genome-wide perturbation screen identifies the ribonucleoprotein Hnrnpk as rate-limiting for prion propagation.

Journal: The EMBO journal

Published: August 10, 2022

Glial activation in prion diseases is selectively triggered by neuronal PrPSc.

Glial activation in prion diseases is selectively triggered by neuronal PrPSc.

Journal: Brain pathology (Zurich, Switzerland)

Published: December 07, 2021

A conformational switch controlling the toxicity of the prion protein.

A conformational switch controlling the toxicity of the prion protein.

Journal: Nature structural & molecular biology

Published: December 01, 2021

Calreticulin mutations affect its chaperone function and perturb the glycoproteome.

Calreticulin mutations affect its chaperone function and perturb the glycoproteome.

Journal: Cell reports

Published: July 08, 2021

Loss of PIKfyve drives the spongiform degeneration in prion diseases.

Loss of PIKfyve drives the spongiform degeneration in prion diseases.

Journal: EMBO molecular medicine

Published: June 15, 2021

Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice.

Soluble dimeric prion protein ligand activates Adgrg6 receptor but does not rescue early signs of demyelination in PrP-deficient mice.

Journal: PloS one

Published: July 31, 2020

Toward Therapy of Human Prion Diseases.

Toward Therapy of Human Prion Diseases.

Journal: Annual review of pharmacology and toxicology

Published: September 30, 2017

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity.

Inhibition of group-I metabotropic glutamate receptors protects against prion toxicity.

Journal: PLoS pathogens

Published: September 08, 2017

GPR56/ADGRG1 regulates development and maintenance of peripheral myelin.

GPR56/ADGRG1 regulates development and maintenance of peripheral myelin.

Journal: The Journal of experimental medicine

Published: October 09, 2016

Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.

Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.

Journal: Blood

Published: February 01, 2016

The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6.

The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6.

Journal: Nature

Published: December 22, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026